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DOI 10.1016/j.ccr.2009.11.022SUMMARYMET amplification activates ERBB3/PI3K/AKT signaling in EGFRmutant lung cancers and causes resistance
to EGFR kinase inhibitors. We demonstrate that MET activation by its ligand, HGF, also induces drug resis-
tance, but through GAB1 signaling. Using high-throughput FISH analyses in both cell lines and in patients
with lung cancer, we identify subpopulations of cells withMET amplification prior to drug exposure. Surpris-
ingly, HGF accelerates the development ofMET amplification both in vitro and in vivo. EGFR kinase inhibitor
resistance, due to either MET amplification or autocrine HGF production, was cured in vivo by combined
EGFR and MET inhibition. These findings highlight the potential to prospectively identify treatment naive,
patients with EGFR-mutant lung cancer who will benefit from initial combination therapy.INTRODUCTION
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibi-
tors (TKIs) gefitinib and erlotinib are effective clinical therapies for
patients with advanced non-small cell lung cancer (NSCLC) who
have EGFR-activating mutations (Asahina et al., 2006; Inoue
et al., 2006; Rosell et al., 2009; Sequist et al., 2008; Tamura
et al., 2008). A recent phase 3 clinical trial demonstrated that
patients with EGFR-mutant NSCLC had superior outcomes
with gefitinib treatment, compared with standard first-line cyto-
toxic chemotherapy (Mok et al., 2009). However, despite these
dramatic benefits from EGFR TKIs in this genetically definedSIGNIFICANCE
The therapeutic success of EGFR tyrosine kinase inhibitors (T
ment of drug resistance, mediated by MET amplification in a su
present in a small fraction of cells before drug exposure, and i
These findings provide insight into the origins of drug resistanc
nation treatment strategies as initial therapies, specifically in a
existing MET amplification.cohort, all of these patients ultimately develop resistance
(referred to here as ‘‘acquired resistance’’) to gefitinib and erloti-
nib. Two mechanisms of acquired resistance have been vali-
dated in patients. Secondary mutations in EGFR itself, including
the EGFR T790M ‘‘gatekeeper’’ mutation is observed in 50% of
resistance cases, and amplification of the MET oncogene is
observed in 20% of resistance cases (Balak et al., 2006; Bean
et al., 2007; Engelman et al., 2007b; Kobayashi et al., 2005;
Kosaka et al., 2006; Pao et al., 2005). Both resistance mecha-
nisms lead to maintenance of ERBB3/PI3K/AKT signaling in
the presence of gefitinib (reviewed in Engelman and Janne,
2008).KIs) in EGFR-mutant lung cancers is limited by the develop-
bset of patients. Here, we observe thatMET amplification is
ts emergence is dramatically accelerated by its ligand, HGF.
e in EGFR-mutant cancers and support a rationale for combi-
molecularly defined cohort of patients with evidence of pre-
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Preexisting MET Amplified ClonesIn addition to these genetic alterations, activation of IGF-1Rb/
IRS-1 signaling through loss of IGF-binding proteins also drives
gefitinib resistance in EGFR wild-type cancer cell lines (Guix
et al., 2008). Additionally, a recent study suggested that the
MET ligand, HGF, can promote short-term resistance in two
EGFR mutated cancer cell lines (Yano et al., 2008). Both ligand-
dependent resistance mechanisms maintain PI3K/AKT activa-
tion despite EGFR inhibition. However, differences between
IGF- and HGF-driven resistance in terms of potency and activa-
tion of downstream signaling pathways have yet to be thoroughly
examined. Furthermore, the contribution of HGF, if any, to gefiti-
nib resistance mediated by MET amplification is unknown.
Strategies for overcoming acquired resistance to gefitinib are
now undergoing clinical evaluation. In preclinical studies, the
EGFR T790M mutation can be overcome by second-generation,
irreversible EGFR inhibitors (Engelman et al., 2007a; Kobayashi
et al., 2005; Riely, 2008). In addition, the growth of EGFR-mutant
cancers with MET amplification can be inhibited by combined
treatment with EGFR and MET kinase inhibitors (Bean et al.,
2007; Engelman et al., 2007b). Indeed, there are now clinical
trials assessing both irreversible EGFR inhibitors and a combina-
tion of MET and EGFR inhibitors in patients with acquired resis-
tance to gefitinib and erlotinib. Furthermore, clinical activity of
the irreversible EGFR inhibitor, PF00299804, has been observed
in patients with NSCLC who have developed acquired resistance
to gefitinib and erlotinib (Janne et al., 2008). As an alternative
strategy, to delay or avoid the emergence of resistance, there
is increased enthusiasm for using agents that are effective
against specific resistance mechanisms as initial systemic
therapies. For example, PF00299804 is now being assessed in
a phase 2 clinical trial of EGFR TKI–naive patients. However,
there are currently no methods to predict the specific resistance
mechanism that a cancer will develop.
In the current study, we modeled in vitro resistance to
PF00299804 in the TKI-sensitive EGFR-mutant NSCLC cell line
HCC827 (Engelman et al., 2006; Engelman et al., 2007b; Ogino
et al., 2007). In addition, we evaluated the potency of the MET
ligand, HGF, to promote resistance to EGFR TKIs and deter-
mined whether MET amplification preexists in a subpopulation
of cells before treatment with a TKI.
RESULTS
METAmplificationCausesResistance to the Irreversible
EGFR Inhibitor PF00299804 by Activating ERBB3
Signaling
We generated in vitro–resistant clones of HCC827 cells to the
irreversible pan-ERBB kinase inhibitor, PF00299804, using
methods described elsewhere (Engelman et al., 2006; Engelman
et al., 2007b). HCC827 cells were exposed to increasing concen-
trations of PF00299804, starting with 1 nM, until they were able
to proliferate freely in 1 mM PF00299804, which occurred after
six months of drug selection. This concentration was chosen
because it is 1000-fold greater than the IC50 for growth inhibi-
tion of HCC827 cells and approximately five times greater than
the serum concentration of PF00299804 observed in patients
with NSCLC in the phase 1 clinical trial (Janne et al., 2008;
Schellens et al., 2007). Five independent clones were isolated
and expanded for further studies. All five HCC827 PF00299804-78 Cancer Cell 17, 77–88, January 19, 2010 ª2010 Elsevier Inc.resistant (PFR) clones were resistant to PF00299804 in vitro
(Figure 1A and data not shown). No secondary EGFR mutations
(e.g., T790M) were detected in any of the clones (data not shown).
We next examined the effects of PF00299804 on EGFR,
ERBB3, AKT, and ERK phosphorylation in the HCC827 PFR
clones. Unlike in parental HCC827 cells, ERBB3 activation and
downstream PI3K/AKT and ERK signaling are maintained in
the presence of PF00299804 in HCC827 PFR cells (Figure 1B).
We also observed increased total MET protein in the HCC827
PFR cells, and combined MET and EGFR inhibition down-regu-
lated ERBB3, AKT, and ERK phosphorylation as well as the
modest EGFR phosphorylation that was maintained in the
presence of PF00299804 alone (Figure 1B). This behavior
following treatment with PF00299804 alone or in combination
with a MET inhibitor is similar to that observed in gefitinib-resis-
tant HCC827 cells (HCC827 GR cells), which were generated in
an analogous manner and contained a focal amplification in
chromosome 7 harboring the MET oncogene (Engelman et al.,
2007b).
Given the similarities in the HCC827 PFR and GR cells following
treatment with either PF00299804 or gefitinib, respectively,
we determined whether the addition of a MET inhibitor would
overcome resistance to PF00299804. We used both a tool
compound PHA-665,752 and the MET inhibitor PF02341066
currently undergoing clinical development (Figure 1C, upper
panel; data not shown) (Zou et al., 2007). The combination of
PF00299804 and a MET inhibitor effectively inhibited the growth
of HCC827 PFR cells, whereas neither agent alone led to growth
inhibition (Figure 1C, upper panel; data not shown). In addition,
the combination of gefitinib and PF02341066 also effectively
inhibited the growth of HCC827 PFR cells (Figure 1C, lower
panel). These findings further suggest that the resistance
mechanism in the HCC827 PFR cells is not unique or dependent
on the differences between reversible (gefitinib) or irreversible
(PF00299804) EGFR inhibitors, but rather is due solely to
MET signaling. We also evaluated the effects of the irreversible
EGFR inhibitor PF00299804 and the MET inhibitor PF-
02341066 in an HCC827 PFR xenograft model. Treatment with
PF00299804 alone was modestly more effective than treatment
with PF02341066 alone, but the tumors demonstrated resistance
to PF00299804. However, combined MET and EGFR inhibition
completely inhibited tumor growth and produced complete
responses (p < 0.0001; Figure 1D). In fact, the combination treat-
ment was discontinued after 56 days (Figure 1D, arrow), and no
tumor regrowth has been observed to date in any of the xeno-
grafts (after more than 35 weeks without therapy) (Figure 1D),
suggesting that the mice have been cured.
We next determined whether the increase in MET protein
expression was due to MET amplification in the HCC827 PFR
cells (Figure 2A). All of the PFR clones contained at least a
4-fold amplification of MET, similar to the amplification previ-
ously observed in the gefitinib-resistant HCC827 (HCC827 GR)
cells (Engelman et al., 2007b);Figure 2A). All of the PFR clones
also had higher levels of MET protein expression (Figure 2B).
Genomewide SNP analysis revealed that the only area of signif-
icant copy number gain in HCC827 PFR cells is on distal chromo-
some 7, similar to that observed in HCC827 GR cells, and
contains the MET oncogene (Figures 2C and 2D). Furthermore,
HCC827 PFR and GR cells share single copy losses of 4p, 5q,
Figure 1. HCC827 PFR Cells Are Resistant to PF00299804, but Combined MET and EGFR Inhibition Blocks PI3K/AKT and ERK Signaling and
Restores Sensitivity in Vitro and In Vivo
(A) Parental and resistant HCC827 PFR5 cells treated with increasing concentrations of PF00299804. Cell viability relative to untreated controls measured after
72 hr. Each data point represents the mean ± SD of 6 wells.
(B) HCC827 and HCC827 PFR5 and PFR6 cells were treated for 6 hr with 1 mM PF00299804 or gefitinib, PHA-665,752, or their combination. Cell lysates were
immunoblotted to detect indicated proteins.
(C) Upper panel: HCC827 PFR6 cells treated with increasing concentrations of PF00299804, PF2341066, or their combination. Lower panel: HCC827 PFR6 cells
treated with increasing concentrations of gefitinib alone or in combination with PF2341066. Cell viability relative to untreated controls measured after 72 hr. Each
data point represents the mean ± SD of 6 wells.
(D) HCC827 PFR xenografts in nu/nu mice were treated with PF2341066, PF00299804, or their combination. Tumors measured twice weekly. Only combination
treatment led to tumor shrinkage and was the most effective treatment in vivo (p < 0.0001). Treatment was stopped after 56 days (arrow) and no tumor regrowth
was observed in 35 weeks. Each data point represents the mean ± SD for five mice.
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Preexisting MET Amplified Clones14p, 14q, and 19p, but only HCC827 PFR cells have a single
copy loss of 16q. Intriguingly, further examination of the region
of MET amplification on distal chromosome 7 in both sets of
clones showed that, although the copy number changes within
the amplicons are not identical in the HCC827 GR and PFR cells,
the size and the proximal borders of the amplicons are very
similar (Figure 2D). Together these findings, along with the
multiple shared regions of single copy genomic loss between
the HCC827 PFR and GR cells, suggest that the resistant clones
may have arisen from a common origin.
HGF Activates PI3K/AKT Signaling through GAB1
and Leads to gefitinib Resistance
MET amplification was previously shown to cause gefitinib
resistance in HCC827 GR cells (Engelman et al., 2007b). We
investigated whether activation of MET signaling by its ligand,
HGF, could also cause resistance to gefitinib and other ERBB-
targeted therapies. In a 72-hr survival assay, HGF induced
substantial gefitinib resistance in HCC827 cells that was
abolished by the addition of PHA-665,752 (Figure 3A). Further-
more, HGF maintained PI3K/AKT, mTORC1, and ERK activation
in the presence of gefitinib in a dose-dependent mannerthat mirrored its capacity to maintain cell viability (Figures 3B
and 3C).
We also determined the capacity for HGF to maintain down-
stream signaling and cell viability in other EGFR- and HER2-
addicted cancers. In cell lines with EGFR exon 19 deletions
(HCC827 and PC-9), and an EGFR-driven lung cancer cell
line carrying the T790M resistance mutation (H1975), HGF
restored PI3K/AKT, mTORC1, and ERK signaling, despite
continued EGFR inhibition in the presence of 1 mM gefitinib or
PF00299804 (Figure 3D). HGF also rescued each of these cell
lines from TKI-induced cell death after 72 hr (Figure 4A and
Figures S1A–S1E, available with this article online). In contrast
to the EGFR-addicted cancers, HGF did not rescueHER2 ampli-
fied breast cancer cell lines from the effects of lapatinib
(Figure 4A and Figures S1F and S1G), nor did it rescue AKT or
mTORC1 signaling in either HER2-driven cell line (Figure 3D).
Thus, the capacity to rescue cell viability appears to strongly
correlate with capacity to restore downstream signaling, espe-
cially along the PI3K/AKT pathway. We suspect that HGF had
a minimal effect in BT-474 and SKBR3 cells because these cell
lines have lower levels of MET expression than do the other
EGFR-driven cell lines that were tested.Cancer Cell 17, 77–88, January 19, 2010 ª2010 Elsevier Inc. 79
Figure 2. HCC827 PFR Cells Have a Focal Amplification in MET That Is Similar to HCC827 GR Cells
(A) MET copy number determined by quantitative PCR. Parental (Par) HCC827 and MET-amplified HCC827 GR (GR5) cells were used as negative and positive
controls, respectively. Each column represents the mean ± SD for three independent experiments.
(B) Parental HCC827 cells and PFR clones were immunoblotted to detect indicated proteins.
(C) Genomewide view of copy number changes generated using Human Mapping 250K Sty single nucleotide polymorphism (SNP) array and analyzed using the
dChip program (see Experimental Procedures). HCC827 GR clones were compared with HCC827 PFR and HCC827 parental clones. Blue curve indicates degree
of amplification of each SNP from 0 (left) to 8 (right).
(D) Chromosome 7 view of copy number changes in HCC827 parental, GR, and PFR cells. Arrow indicates MET oncogene.
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Preexisting MET Amplified ClonesTo confirm the ability of HGF to induce resistance to EGFR
TKIs, we introduced the human HGF gene into HCC827 cells
(HCC827-HGF). Parental HCC827 cells secrete undetectable
levels of HGF; however, HCC827-HGF cells express HGF protein
(Figure S2A) and secrete approximately 70 ng/ml HGF into the
culture medium (data not shown). Furthermore, HCC827-HGF
cells are gefitinib resistant (Figure S2B) and maintain PI3K/
AKT, ERK, and mTOR signaling in the presence of gefitinib
(Figure S2A); however, gefitinib sensitivity is restored with the
addition of a MET inhibitor (Figure S2B). We also evaluated the
capacity of HGF to induce gefitinib resistance in vivo using an
HCC827-HGF xenograft model. We have previously shown
that parental HCC827 cells demonstrate complete responses
to gefitinib in vivo (Engelman et al., 2006; Engelman et al.,
2007a). However, the HCC827-HGF xenografts demonstrated
resistance (Figure 3E). Treatment with gefitinib alone was slightly
more effective than no treatment or treatment with PF02341066
alone, but only the combination of gefitinib and PF02341066
completely inhibited tumor growth (p < 0.001; gefitinib versus
gefitinib/PF2341066; Figure 3E). Indeed, three of four mice
were cured after 70 days of combined treatment with no evi-
dence of regrowth 70 days after stopping treatment.
Because HGF ligand appeared to be a potent inducer of resis-
tance to RTK inhibitors, we compared its efficacy to that of IGF
ligand, which we had previously found to cause gefitinib resis-
tance in A431 cells (Guix et al., 2008). Although IGF exposure
led to significant rescue from gefitinib-induced cell death in
A431 cells and to partial rescue in HN11 EGFR wild-type cells,
the other five cell lines tested remained sensitive to ERBB inhibi-
tion despite the presence of IGF (Figure 4A and Figure S1). Inter-80 Cancer Cell 17, 77–88, January 19, 2010 ª2010 Elsevier Inc.estingly, in three of those cell lines (BT-474, HCC827, and
H1975), IGF was unable to maintain PI3K/AKT signaling despite
potent activation of IGR-1Rb (Figure 4B and Table S1). Of note,
IGF did not restore ERK phosphorylation in any of the six cell
lines examined, including those in which it induced IGF-1Rb or
PI3K/AKT activation or both (Figure 4B). Thus, unlike IGF, HGF
may be more potent at promoting resistance because it leads
to activation of both the PI3K/AKT and ERK pathways. Unex-
pectedly, IGF restored PI3K/AKT signaling in PC-9 cells, but
these cells still remained highly sensitive to EGFR inhibition
after 72 hr (Figure 4A and Figure S1C). This disconnect between
maintenance of PI3K/AKT signaling and lack of an effect on cell
viability is not due to a brief, transient restoration of downstream
signaling, because we observed that IGF maintained PI3K
signaling in PC-9 cells for at least 24 hr in the presence of gefiti-
nib (data not shown).
MET-amplified, gefitinib-resistant HCC827 GR cells utilize
ERBB3 as the primary adaptor to activate PI3K/AKT signaling
(Engelman et al., 2007b). Although HGF treatment was sufficient
to rescue AKT phosphorylation in several EGFR-driven cell lines
in the presence of TKIs, ERBB3 phosphorylation was not
restored (Figure 3D). This finding suggests that HGF-induced
MET activation utilizes an adaptor other than ERBB3 to activate
PI3K signaling. To determine which PI3K adaptors were being
utilized to maintain HGF-mediated PI3K signaling, we immuno-
precipitated the p85 regulatory subunit of PI3K and examined
coprecipitating phosphotyrosine proteins (Engelman et al., 2005;
Engelman et al., 2007b; Guix et al., 2008). As expected, treat-
ment with a TKI disrupted the association of ERBB3 (and other
phosphotyrosine proteins) with p85, and the addition of HGF
Figure 3. HGF Induces MET-Dependent Resistance Only in Cell Lines in which It Activates PI3K/AKT, ERK, and mTORC1 Signaling
(A and B) HCC827 cells treated with increasing concentrations of gefitinib alone or in combination with PHA-665,752, in the absence or presence of HGF (50 ng/ml)
(A), or increasing concentrations of gefitinib alone or in combination with the indicated concentrations of HGF (B). Cell viability relative to untreated controls
measured after 72 hr. Each data point represents the mean ± SD of 6 wells.
(C) HCC827 cells were treated for 6 hr with 1 mM gefitinib alone or in combination with the indicated concentrations of HGF. Cell lysates were immunoblotted to
detect indicated proteins.
(D) Cells were treated for 6 hr with gefitinib (HCC827, PC-9), PF00299804 (H1975), or lapatinib (BT-474, SKBR3), alone or in combination with HGF (50 ng/ml). All
drugs were used at 1 mM. Cell lysates were immunoblotted to detect indicated proteins. Asterisk indicates cross-reaction by the p-EGFR antibody against
p-HER2. Cell lines in which HGF rescued viability are labeled in blue, and cell lines in which HGF did not rescue viability are labeled in red.
(E) HCC827-HGF xenografts in nu/nu mice treated with PF2341066, gefitinib, or their combination and tumors measured twice weekly. Some growth inhibition
was observed with gefitinib alone; however, only combination treatment led to complete tumor shrinkage (p = 0.002). Each data point represents the mean ± SD
for five mice. See also Figure S2.
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Preexisting MET Amplified Clonesdid not restore the interaction (Figure 5A). However, we observed
that HGF potently induced the association between p85 and
Grb2 associated binder 1 (GAB1), which runs as a broad, highly
tyrosine-phophorylated band at approximately 110 kDa.
To more directly assess whether GAB1 mediates HGF-
mediated activation of PI3K/AKT signaling and cell viability, we
used small interfering RNA (siRNA) to knockdown GAB1 expres-
sion in the HCC827 cells. Knockdown of GAB1 reduced HGF-
mediated rescue of PI3K/AKT signaling (Figure 5B) and inhibited
the ability of HGF to rescue HCC827 cells from gefitinib-induced
cell death (Figure 5C). Of note, although the addition of HGF
leads to substantial loss of GAB1 protein (Figure 5B), the amount
of tyrosine phosphorylated GAB1 is dramatically increased
(Figure S3), and this facilitates the efficient coupling to PI3K
(Figure 5A). Thus, activation of HGF/MET signaling can lead
to gefitinib resistance in EGFR-mutant cancers by activating
PI3K/AKT signaling through two different adaptors: ERBB3
when MET is activated by genomic amplification or GAB1
when MET is activated by HGF.Transient HGF Exposure Leads to Stable Ligand-
Independent Gefitinib Resistance in HCC827-50GR
Cells through Selection of a PreexisitingMET-Amplified
Clone
Because HGF-induced resistance to EGFR TKIs appears
intimately linked to ligand-induced activation of downstream
signaling, we hypothesized that long-term resistance would
require continuous exposure to HGF. We observed that, by
replenishing cells with HGF in combination with the EGFR TKI
every 3 days, cells continue to be highly resistant indefinitely
(data not shown). Thus, we treated each cell line with HGF in
the presence of an EGFR inhibitor for 14 days and then removed
HGF, but maintained the cells in the EGFR TKI. Surprisingly,
HCC827 cells treated transiently with HGF remained perma-
nently resistant to gefitinib after HGF withdrawal (Figures 6A
and 6B). These stably resistant cells were termed HCC827-
50GR (50 ng HGF Gefitinib Resistant) cells (Figure 6A). In
contrast, HCC827 cells that are not pretreated with HGF develop
gefitinib resistance only after six months of gradually increasingCancer Cell 17, 77–88, January 19, 2010 ª2010 Elsevier Inc. 81
Figure 4. IGF Rescues PI3K/AKT and
mTORC1 Signaling in Some Cell Lines but
Fails to Activate ERK
(A) IC50 values for viability curves (Figure S1) in the
presence or absence of HGF and IGF. Cells were
treated with increasing concentrations of the
appropriate TKI alone (red) or in combination
with 50 ng/ml HGF (blue) or 75 ng/ml IGF (green).
(B) Cells were treated for 6 hr with gefitinib
(HCC827, PC-9, A431, HN11), PF00299804
(H1975), or lapatinib (BT-474, SKBR3) alone or in
combination with HGF (50 ng/ml) or IGF (75 ng/ml).
All drugs were used at 1 mM. Cell lysates were
immunoblotted to detect indicated proteins.
BT-474 and SKBR3 cell lysates were run on the
same gel, and no MET or IGF-1Rb was detected
in SKBR3 cells relative to BT-474 cells. See also
Table S1 for quantification.
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Preexisting MET Amplified Clonesconcentrations of drug exposure (Engelman et al., 2007b). In
addition, when HCC827-50GR cells were grown in media alone
(without gefitinib) for eight weeks, these cells (HCC827-50GR
[8wksR5]) maintained their resistance (Figure S4A). Treatment
with HGF alone (without gefitinib) for 14 days did not yield stably
resistant cells (Figure S4C and Table S2). Thus, lasting resis-
tance conferred by transient HGF requires the selective pressure
of gefitinib during ligand exposure.
Stably resistant HCC827-50GR cells maintained PI3K/AKT,
mTORC1, and ERK activation in the presence of gefitinib.
Surprisingly, ERBB3 also remained phosphorylated in HCC827-
50GR cells treated with gefitinib (Figure S4B), which suggests
that, although initial HGF-mediated resistance mechanisms
utilized GAB1 to activate PI3K/AKT signaling, the ligand-inde-
pendent HCC827-50GR cells utilize ERBB3 to activate PI3K/
AKT signaling. This observation suggests that short-term
exposure to HGF may lead HCC827 cells to develop or select
the same mechanism of stable resistance, through activation
of ERBB3/PI3K signaling, as was observed in MET-amplified
HCC827 GR cells (Engelman et al., 2007b). Unlike the HCC827
cells, several other EGFR-driven cancer cell lines that were
made resistant to EGFR TKIs by HGF treatment did not maintain
stable ligand-independent resistance after the withdrawal of
HGF (Figures S4D–S4F and Table S3). These findings suggest
that HCC827 cells are uniquely poised to develop stable ligand-
independent resistance.
Stably resistant HCC827-50GR cells had increased total MET
protein levels, compared with parental cells, and maintained82 Cancer Cell 17, 77–88, January 19, 2010 ª2010 Elsevier Inc.MET phosphorylation in the presence of
gefitinib (Figure S4B), mimicking MET-
amplified HCC827 GR cells. Therefore,
we examined MET copy number using
fluorescent in situ hybridization (FISH),
and found significant MET copy number
gains in HCC827-50GR cells, compared
with parental cells (Figure 6C). Quantita-
tive PCR demonstrated a 3- to 4-fold
amplification of MET, similar to the
HCC827 GR and PFR cells (data not
shown). These results suggest that METamplification may be driving ERBB3/PI3K/AKT signaling and
gefitinib resistance in HCC827-50GR cells.
To examine this hypothesis, we exposed HCC827-50GR cells
to PHA-665,752 alone or in combination with gefitinib. Only the
combination of gefitinib and PHA-665,752 resulted in a substan-
tial reduction in the number of viable cells (Figure 6D, upper
panel). In addition, the HCC827-50GR (8wks R5) cells (grown
in media without gefitinib for eight weeks) also remained
sensitive only to the combination of MET and EGFR inhibition
(Figure 6D, lower panel). Furthermore, treatment with gefitinib
in combination with PHA-665,752 completely blocked ERBB3
phosphorylation as well as downstream PI3K/AKT, mTORC1,
and ERK signaling in HCC827-50GR and HCC827-50GR(8wks
R5) cells (Figure 6E). Taken together, these results suggest that
MET inhibition restores EGFR dependence and gefitinib sensi-
tivity in HCC827-50GR cells.
These results led us to examine tissue sections from HCC827-
HGF xenograft models treated with gefitinib (Figure 3E). Of three
tumors that developed gefitinib resistance, one exhibited signif-
icant MET amplification (Figure 7A). Thus, MET amplification is
also facilitated by HGF in vivo.
Because HCC827 GR, PFR and 50GR cells all eventually
develop focal MET amplification as a resistance mechanism,
we hypothesized that parental HCC827 cells may harbor a
preexisting MET-amplified clone. We analyzed 4237 individual
HCC827 cell nuclei using high-throughput FISH (Experimental
Procedures) and identified six (0.14%) of 4237 cells that
harbored significant MET copy number gains (Figures 7B and
Figure 5. HGF Rescue of PI3K/AKT Signaling Is Mediated through GAB1 Instead of ERBB3
(A) Cells treated for 6 hr with gefitinib (HCC827, PC-9), PF00299804 (H1975), or lapatinib (BT-474, SKBR3), alone or in combination with HGF (50 ng/ml). All drugs
were used at 1 mM. Cell extracts were immunoprecipitated with an anti-p85 antibody followed by western blot with anti-p-Tyr, anti-ERBB3, and anti-p85
antibodies.
(B) HCC827 cells were transfected with a negative control or GAB1 siRNA for 48 hr. Transfected cells were treated for 6 hr with gefitinib (1 mM) alone or in
combination with HGF (50 ng/ml). Cell lysates were immunoblotted to detect indicated proteins. See also Figure S3.
(C) HCC827 cells were transfected with GAB1 siRNA or a negative control siRNA for 48 hr, then treated with increasing concentrations of gefitinib, alone or in
combination with 50 ng/ml HGF. Left panel: cell viability relative to untreated controls measured after 72 hr. Each data point represents the mean ± SD of 6 wells.
Right panel: plot of IC50 values corresponding to cell viability curves.
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Preexisting MET Amplified Clones7C). These results were confirmed in an independent experiment
using a second gefitinib-sensitive parental HCC827 cell line
(HCC827 N1; Figure 7C). We also generated two subclones
derived from single cells from the gefitinib-sensitive parental
HCC827 cell line (HCC827 C1 and C2). Both subclones were
sensitive to gefitinib in vitro (data not shown), and each also con-
tained a low-frequency population of MET-amplified cells (Fig-
ure 7C). We further examined the gefitinib-sensitive H3255 and
PC-9 cells using FISH. Gefitinib-resistant clones of both H3255
and PC-9 have been isolated and reported to contain the
EGFR secondary resistance mutation T790M but notMET ampli-
fication (Engelman et al., 2006; Ogino et al., 2007). We did not
detect a subpopulation of MET-amplified cells in the H3255 or
the PC-9 cells (Figure 7C).
We hypothesized that the mechanism by which transient
treatment with HGF and gefitinib leads to the generation of
MET-amplified HCC827-50GR cells is by selecting this small
population of preexisting MET amplified cells out from the
parental HCC827 cell population. To test this hypothesis, we
spiked unlabeled HCC827 parental cells with 0.1% of either
GFP-labeled HCC827 cells or GFP-labeled MET-amplified
HCC827 GR6 cells. We treated these two populations with either
media alone (no selection) or with gefitinib in combination with
HGF. Media was changed and fresh HGF was added every
72 hr, and cells were collected after 19 days for FACS to quantify
the percent of cells with GFP expression (Figure S5A). As
expected, there was no significant change in the percentage of
GFP-labeled HCC827 cells at the end of 19 days. However,the percentage of GFP labeled MET-amplified HCC827 GR6
cells increased over 300-fold to almost 33% in just over two
weeks (Figure 7D). Taken together, these results suggest that
HGF exposure in the presence of an EGFR inhibitor leads to
the rapid selection of a preexisting MET-amplified clone in the
HCC827 cells (Figure S5B).
Analyses of Tumors with Acquired Resistance to
Gefitinib/Erlotinib Reveal Evidence of Pretreatment
MET Amplification and Increased HGF Expression
in Resistant Cancers
To determine the clinical implications of these in vitro and in vivo
observations, we examined tumor specimens from gefitinib- or
erlotinib-treated patients with EGFR-mutant NSCLC (Figure 8).
All patients had a clinical partial tumor response to gefitinib or
erlotinib treatment and subsequently developed clinical drug
resistance. We evaluated 27 patients, 16 with paired specimens
obtained before and after geftinib or erlotinib treatment and
11 with drug resistance specimens alone. All specimens, when
feasible, were evaluated for MET amplification, HGF expression
by immunohistochemistry (IHC), and the presence of EGFR
T790M (Figure 8 and Figure S6). We observed EGFR T790M in
55% (15 of 27) andMET amplification in 15% (4 of 27) of resistant
tumor specimens. In patients with paired tumor specimens, HGF
expression was higher in the drug-resistant specimens than in
the pretreatment specimens (p = 0.025, Wilcoxon signed-rank
test). In patients with drug-resistant specimens alone, HGF
expression was similar to that of drug-resistant specimens inCancer Cell 17, 77–88, January 19, 2010 ª2010 Elsevier Inc. 83
Figure 6. Transient HGF Exposure Leads to MET Amplification and Stable Ligand-Independent Gefitinib Resistance in HCC827 Cells
(A) HCC827 cells treated with HGF (50 ng/ml) and 1 mM gefitinib are resistant to gefitinib (HCC827-50 cells). After the removal of HGF, stably resistant HGF-inde-
pendent HCC827-50GR cells survive in 1 mM gefitinib alone. In contrast, parental HCC827 cells do not survive when treated with 1 mM gefitinib.
(B) Parental HCC827 cells and HCC827-50 cells (pretreated with gefitinib in combination with HGF [50 ng/ml] for 14 days) were grown in media alone (No Rx) or
media treated with 1 mM gefitinib (+Gef) for 7 days. Viable cells were visualized and quantified using Syto60 staining.
(C) Fluorescence in situ hybridization (FISH) of MET/EGFR/CEP7 probe set with HCC827 and HCC827-50GR cells: MET, orange; EGFR, green; and CEP7, aqua.
Metaphase spread (bottom) shows multiple copies of EGFR and MET (arrow) on individual chromosomes. Scale bars represent 10 mm.
(D) HCC827-50GR cells (upper panel) and HCC827-50GR cells grown in media alone (without gefitinib) for 8 weeks, 50GR 8wks R5 (lower panel), were treated
with increasing concentrations of gefitinib or PHA-665,752 or their combination for 72 hr. Cell viability was measured relative to untreated controls. Each data
point represents the mean ± SD of 6 wells.
(E) HCC827 cells and stably resistant HCC827-50GR cells were treated for 6 hr with gefitinib, PHA-665,752, or their combination. All drugs were used at 1 mM. Cell
lysates were immunoblotted to detect indicated proteins. See also Figure S4 and Tables S2 and S3.
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Preexisting MET Amplified Clonespatients with paired tumor specimens. Together, these findings
support our in vitro and in vivo studies on HGF mediating resis-
tance to EGFR TKIs.
We further evaluated the pretreatment specimens for evi-
dence of MET amplification. In all four patients with MET ampli-
fication in the drug-resistant specimens, we observed rare (<1%)
tumor cells with MET amplification from the corresponding
pretreatment specimens (Figures 8A and 8B). In contrast, of
eight cases of resistant cancers without MET amplification, we
observed rare MET-amplified tumor cells in only one corre-
sponding pretreatment tumor specimen. These findings are
consistent with cell line data (Figures 7B and 7C), where we
observed evidence of preexisting MET amplification only in the
cell line that subsequently develops MET amplification as its
resistance mechanism.
DISCUSSION
Kinase inhibitors have emerged as effective clinical therapies for
cancers that exhibit oncogene addiction to a particular kinase.
(Demetri et al., 2002; Druker et al., 2001; Inoue et al., 2006;84 Cancer Cell 17, 77–88, January 19, 2010 ª2010 Elsevier Inc.Mok et al., 2009; Sequist et al., 2008). However, the clinical
success of treatment with kinase inhibitors is uniformly limited
by the development of drug resistance. To date, resistance
mechanisms have predominately involved secondary genomic
alterations in the target kinase that alter either the physical
(such as steric hindrance) or biochemical (change in ATP affinity)
properties of the receptor and result in drug resistance (Gorre
et al., 2001; Shah et al., 2002; Yun et al., 2008). We have previ-
ously described MET amplification as a mechanism of gefitinib
resistance in EGFR-mutant cancers (Engelman et al., 2007b),
leading to persistent activation of both PI3K/AKT and ERK
signaling in the presence of the EGFR TKI (Engelman et al.,
2007b).
A critical question for all resistance mechanisms to kinase
inhibitors is whether they occur as a result of treatment or
whether they preexist prior to treatment and are selected out
during the course of therapy. At least some imatinib-resistant
CML clones are thought to be present at low levels before treat-
ment and undergo clonal selection during imatinib exposure
(Hofmann et al., 2003; Roche-Lestienne et al., 2002, 2003;
Shah et al., 2002). Similarly, EGFR T790M can be detected at
Figure 7. HGF Treatment Selects out a Small Preexisting Population of MET-Amplified HCC827 Cells from the Parental Population In Vitro
and In Vivo
(A) Fluorescence in situ hybridization (FISH) of MET/EGFR/CEP7 probe set: MET, red; EGFR, green; and CEP7, aqua. Left panel, tumor sections from control
HCC827 xenograft models that do not express HGF showed normal MET copy number. Right panel, tumor sections from one of three HCC827-HGF xenografts
treated with gefitinib (Figure 3E) showed significant MET amplification.
(B) High-throughput FISH analysis of HCC827 cells identifies a subpopulation harboringMET amplification (arrow). MET (RP-11-95I120; red); 7qter (RP-11-6903;
green). All scale bars represent 10 mm.
(C) Parental HCC827 cells and three independent clones harbor a small percentage of MET-amplified cells. No preexisting MET amplification was detected in
H3255 or PC-9 cell populations.
(D) Left panel: HCC827 cells were spiked with approximately 0.1% of GFP-labeled HCC827 cells or GFP-labeled MET amplified HCC827 GR6 cells. Each pop-
ulation was grown in either media alone or media treated with gefitinib (1 mM) with HGF (50 ng/ml). Cells were collected after 19 days, and GFP levels were quan-
tified using FACS. Each data point for cells treated with gefitinib plus HGF represents the mean ± SD for 3 independent wells. Fold change is the ratio of Day 19
to Day 0 (%GFP). Right panel: diagrammatic depiction of results. See also Figure S5.
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Preexisting MET Amplified Cloneslow levels in patients with EGFR-mutant NSCLC prior to gefitinib
or erlotinib treatment (Maheswaran et al., 2008). Our current find-
ings provide support that this may also be the case for MET
amplification both in HCC827 cells (Figure S5B) and in patients
with EGFR mutant NSCLC who subsequently develop MET
amplification at the time of clinical gefitinib or erlotinib resistance
(Figure 8). The identification of a drug resistance mechanism
from a pretreatment tumor specimen provides the opportunity
to specifically target that resistance mechanism before its emer-
gence. This approach is clinically appealing because combined
treatment with an EGFR and MET inhibitor, specifically in
patients with evidence of MET amplification at baseline, may
lead to a longer time to progression than is currently observed
with gefitinib or erlotinib alone (Asahina et al., 2006; Inoue
et al., 2006; Mok et al., 2009; Rosell et al., 2009; Sequist et al.,
2008; Tamura et al., 2008). In fact, combined EGFR and MET
inhibition in HCC827 cells extinguishes the emergence of MET-
amplified drug-resistant clones (data not shown). However, it
will be critical to learn whether upfront treatment with combina-
tion therapy is tolerable (toxicity) and will provide more clinical
benefit than treatment at the time of relapse.Intriguingly, HCC827 cells appear to be predisposed to the
development of low-levelMET amplification, because subclones
of cells expanded from single-cell clones derived from parental
HCC827 cells (HCC827 N1 and N2) also are found to contain
low levels of MET amplification (Figure 7C). MET is located at
a fragile site in chromosome 7, which facilitates its amplification,
and subsequently a selection for clones harboring MET amplifi-
cation can occur under drug pressure (Hellman et al., 2002).
Why this occurs only in the HCC827 cells and a subset of lung
cancers, and not in other EGFR-mutant cell lines and cancers,
is currently unknown. Collectively, these studies suggest, but
do not prove that the specific mechanisms of resistance that
will develop as a result of drug exposure may be predetermined
and occur as a result of drug selection. Understanding why some
EGFR-mutant cancers are predisposed to develop MET amplifi-
cation will help further refine the clinical development of EGFR
and MET inhibitor combinations.
In this study, we also demonstrate two different and distinct
roles for HGF in mediating EGFR TKI resistance. First, HGF
can independently rescue both PI3K/AKT and ERK signaling in
the presence of gefitinib and lead to drug resistance bothCancer Cell 17, 77–88, January 19, 2010 ª2010 Elsevier Inc. 85
Figure 8. HGF Expression and Preexisting
MET Amplification Can Be Detected in
Tumor Specimens from Patients with
NSCLC
(A) Summary of tumors from geftinib- or erlotinib-
treated patients, including 16 paired and 11 drug-
resistant samples only. Samples were evaluated
for EGFR mutational status, MET amplification,
and HGF expression. Single asterisks indicate
that specimen contained <30% tumor cells. Dou-
ble asterisks denote MET amplification defined
by qPCR, as described elsewhere (Engelman
et al., 2007b). Data on EGFR T790M and MET
amplification in resistant specimens only from
patients 1–4 and 17–19 have been previously pub-
lished (Engelman et al., 2007b). N/A, not available.
(B) FISH analysis of pretreatment sample from
patient 10 shows evidence of a subset of MET-
amplified cells (arrow) before exposure to an
EGFR TKI: MET, RP-11-95I120, orange; CEP 7,
aqua. Scale bars represent 10 mm. See also
Figure S6.
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Preexisting MET Amplified Clonesin vitro and in vivo. Unlike in MET-amplified resistant cancers,
HGF-mediated resistance occurs through GAB1, not ERBB3,
signaling. Higher levels of HGF can be detected in tumor speci-
mens from patients with NSCLC that are clinically resistant to ge-
fitinib or erlotinib, compared with pretreatment tumor specimens
(Figure 8A). Notably, in some patients without evidence of EGFR
T790M or MET amplification, HGF expression is greater in the
resistant specimen (patients 1 and 14; Figure S6C) than in the
pretreatment specimen, supporting a role for HGF alone in
promoting drug resistance. This finding is consistent with prior
observations (Yano et al., 2008). Ligand-mediated drug resis-
tance is unique to HGF because IGF does not rescue TKI-
induced cell death in the majority of cell lines tested. Surprisingly,
IGF did not restore P13K/AKT signaling in most EGFR-mutant
cancers, despite substantial levels of IGF-1Rb expression and
tyrosine phosphorylation. Furthermore, unlike HGF, IGF did not
restore ERK signaling even in cell lines in which it restored
PI3K/AKT signaling in the presence of a TKI. These signaling
differences between HGF and IGF may underlie the lack of
drug resistance induced by IGF. In its second role, HGF acceler-
ates the emergence of MET amplification in HCC827 cells both
in vitro and in vivo. Intriguingly, this process requires concomi-
tant EGFR inhibition, because HGF exposure alone does not
lead to emergence of MET-amplified clones. It is possible that,
in the presence of EGFR inhibition, HGF provides a unique prolif-86 Cancer Cell 17, 77–88, January 19, 2010 ª2010 Elsevier Inc.erative advantage to a subset of cells with
high MET expression (those with amplifi-
cation), thus facilitating their rapid clonal
expansion. Activation of MET signaling
is a unique resistance mechanism to
kinase inhibitors because it can occur
through multiple independent mecha-
nisms, amplification or ligand mediated,
and when combined can lead to rapid
evolution of drug resistance.
Our current findings provide insight into
future therapeutic strategies for the treat-ment of EGFR-mutant NSCLC. Although MET amplification has
been detected in up to 20% of NSCLC patients with the EGFR
mutations who develop acquired resistance to gefitinib or erloti-
nib, activation of MET signaling (by both amplification and
mediated by HGF) may in fact account for a larger fraction of
gefitinib- or erlotinib-resistant tumors. It is tempting to speculate
that HGF production by the stroma may also partially explain
why clinical resistance emerges discordantly in some tissues,
such as the liver, bone, and brain, whereas pulmonary disease
continues to respond to erlotinib treatment (authors’ personal
observation). Our study further implies that the therapeutic
combination of an irreversible EGFR inhibitor (effective against
EGFR T790M) and a MET inhibitor is an attractive treatment
combination for a significant portion of patients with gefitinib-
and erlotinib-resistant, EGFR-mutant NSCLC. In addition, these
findings highlight the potential to prospectively identify treat-
ment-naive patients with EGFR-mutant lung cancer who are
likely to develop MET amplification and may benefit from initial
combination therapy with a MET inhibitor.
EXPERIMENTAL PROCEDURES
Cell Culture Reagents, Viability Studies, and Western Analyses
Cell lines and growth conditions are described in Supplemental Experimental
Procedures. Gefitinib and lapatinib were obtained from commercial sources
(American Custom Chemical Corporation and LC Laboratories, Woburn,
Cancer Cell
Preexisting MET Amplified ClonesMA). PF00299804, PHA-665,752, and PF2341066 were provided by Pfizer
(La Jolla, CA). Cell viability was assessed 72 hr following drug exposure by
Syto60 staining (Invitrogen) or by MTS assay (Promega). Cells were lysed in
an NP-40 containing lysis buffer, separated by SDS-PAGE electrophoresis
and transferred to PVDF membranes. Immunoblotting was performed accord-
ing to the antibody manufacturer’s recommendations. Antibody binding was
detected using enhanced chemiluminescence (PerkinElmer, Waltham, MA).
Generation of In Vitro Drug-Resistant HCC827 Cells
To generate a resistant cell line, HCC827 cells were exposed to increasing
concentrations of PF00299804, similar to our previously described methods
(Engelman et al., 2006; Engelman et al., 2007b). PF00299804 concentrations
were increased stepwise from 1 nM to 1 mM when the cells resumed growth
kinetics, similar to untreated parental cells. To confirm the emergence of a
resistant clone, MTS assays were performed following growth at each
concentration.
In Vivo Treatment Studies
All xenograft studies were performed in accordance with the standards of the
Institutional Animal Care and Use Committee under a protocol approved by
the Animal Care and Use Committee of Massachusetts General Hospital.
Generation and treatment of xenograft models were performed as previously
described and detailed in Supplemental Experimental Procedures (Engelman
et al., 2007a).
SNP Analyses
SNP analyses to evaluate genomewide copy number changes were performed
as described elsewhere (Engelman et al., 2007b). Comparison of gene copy
number between HCC827 and the PFR clones was performed using dChip
software according to previously established methods (Engelman et al.,
2007b; Zhao and Vogt, 2008). SNP data are available from the ncbi gene
expression omnibus database (accession number, GSE18797).
FISH Probes and Hybridization
Bacterial artificial chromosome (BAC) clones CTD-2257H21 (EGFR [7p11.2])
and RP11-95I20 (MET [7q31.2]) were purchased from Children’s Hospital
Oakland Research Institute (Oakland, CA). DNA was extracted using a QIAGEN
kit (Valencia, CA) and labeled with Spectrum Green- or Spectrum Orange-
conjugated dUTP by nick translation (Vysis/Abbott Molecular, Des Plaines,
IL). The CEP7 probe (Vysis/Abbott Molecular, Des Plaines, IL) was used
according to manufacturer’s instructions. Chromosomal mapping and hybrid-
ization efficiency for each probe set were verified in normal metaphase spreads
(data not shown). Three color FISH assays were performed as described
elsewhere (Engelman et al., 2007b).
High Throughput FISH
A Bioview work station with Duet software (Bioview Ltd., Rehovot, Israel) was
used to screen for rare MET-amplified cells. Automatic scans were performed
according to manufacturer’s suggested guidelines after setting classification
criteria for each FISH probe. Images were captured and classified in an auto-
mated fashion and manually reviewed to ensure accuracy. Any unclassified
images were manually reviewed and scored. Any cells that could not be scored
were excluded from the analysis. Paraffin embedded specimens derived from
patients with NSCLC or from xenografts were manually scanned for evidence
of MET amplification.
Patients with NSCLC
Tumor specimens from gefitinib- or erlotinib-treated patients were obtained
from the Dana Farber Cancer Institute/Brigham and Women’s Hospital
(Boston, MA), Massachusetts General Hospital (Boston, MA), the Chinese
University (Hong Kong, China), and Guangdong Provincial People’s Hospital
(Guangzhou, China) under institutional review board-approved studies. All
patients provided written, informed consent. The presence of an EGFR muta-
tion in each specimen was confirmed by exon-specific amplification (exons
18–21), followed by direct sequencing, or using the Surveyor endonuclease
coupled with denaturing HPLC (DHPLC), fractionation and sequencing (Janne
et al., 2006). The EGFR T790M mutation was detected using Surveyor endo-
nuclease coupled with DHPLC or an allele-specific PCR (Janne et al., 2006;Maheswaran et al., 2008). Both methods are capable of detecting the EGFR
T790M mutation at an allele frequency of 1%–5%. HGF immunohistochemistry
was performed as using an anti-HGF 7.2 antibody kindly provided by
Dr. George Vander Woude at the Van Andel Institute (see Supplemental Exper-
imental Procedures).
ACCESSION NUMBERS
Coordinates have been deposited in the NCBI gene expression omnibus
database with accession code GSE18797.
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found with this article online at doi:10.1016/j.ccr.2009.11.022.
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